Literature DB >> 21257639

Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.

Ulziibat Shirendeb1, Arubala P Reddy, Maria Manczak, Marcus J Calkins, Peizhong Mao, Danilo A Tagle, P Hemachandra Reddy.   

Abstract

The purpose of our study was to determine the relationship between mutant huntingtin (Htt) and mitochondrial dynamics in the progression of Huntington's disease (HD). We measured the mRNA levels of electron transport chain genes, and mitochondrial structural genes, Drp1 (dynamin-related protein 1), Fis1 (fission 1), Mfn1 (mitofusin 1), Mfn2 (mitofusin 2), Opa1 (optric atrophy 1), Tomm40 (translocase of outermembrane 40) and CypD (cyclophilin D) in grade III and grade IV HD patients and controls. The mutant Htt oligomers and the mitochondrial structural proteins were quantified in the striatum and frontal cortex of HD patients. Changes in expressions of the electron transport chain genes were found in HD patients and may represent a compensatory response to mitochondrial damage caused by mutant Htt. Increased expression of Drp1 and Fis1 and decreased expression of Mfn1, Mfn2, Opa1 and Tomm40 were found in HD patients relative to the controls. CypD was upregulated in HD patients, and this upregulation increased as HD progressed. Significantly increased immunoreactivity of 8-hydroxy-guanosine was found in the cortical specimens from stage III and IV HD patients relative to controls, suggesting increased oxidative DNA damage in HD patients. In contrast, significantly decreased immunoreactivities of cytochrome oxidase 1 and cytochrome b were found in HD patients relative to controls, indicating a loss of mitochondrial function in HD patients. Immunoblotting analysis revealed 15, 25 and 50 kDa mutant Htt oligomers in the brain specimens of HD patients. All oligomeric forms of mutant Htt were significantly increased in the cortical tissues of HD patients, and mutant Htt oligomers were found in the nucleus and in mitochondria. The increase in Drp1, Fis1 and CypD and the decrease in Mfn1 and Mfn2 may be responsible for abnormal mitochondrial dynamics that we found in the cortex of HD patients, and may contribute to neuronal damage in HD patients. The presence of mutant Htt oligomers in the nucleus of HD neurons and in mitochondria may disrupt neuronal functions. Based on these findings, we propose that mutant Htt in association with mitochondria imbalance and mitochondrial dynamics impairs axonal transport of mitochondria, decreases mitochondrial function and damages neurons in affected brain regions of HD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257639      PMCID: PMC3049363          DOI: 10.1093/hmg/ddr024

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  65 in total

1.  The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains.

Authors:  Ramana V Gutala; P Hemachandra Reddy
Journal:  J Neurosci Methods       Date:  2004-01-15       Impact factor: 2.390

2.  Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.

Authors:  Eugenia Trushina; Roy B Dyer; John D Badger; Daren Ure; Lars Eide; David D Tran; Brent T Vrieze; Valerie Legendre-Guillemin; Peter S McPherson; Bhaskar S Mandavilli; Bennett Van Houten; Scott Zeitlin; Mark McNiven; Ruedi Aebersold; Michael Hayden; Joseph E Parisi; Erling Seeberg; Ioannis Dragatsis; Kelly Doyle; Anna Bender; Celin Chacko; Cynthia T McMurray
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

3.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

4.  Rate and correlates of weight change in Huntington's disease.

Authors:  J M Hamilton; T Wolfson; G M Peavy; M W Jacobson; J Corey-Bloom
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

5.  Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study.

Authors:  K A Bamford; E D Caine; D K Kido; W M Plassche; I Shoulson
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

6.  Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.

Authors:  D E Kuhl; M E Phelps; C H Markham; E J Metter; W H Riege; J Winter
Journal:  Ann Neurol       Date:  1982-11       Impact factor: 10.422

7.  Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function.

Authors:  S Berent; B Giordani; S Lehtinen; D Markel; J B Penney; H A Buchtel; S Starosta-Rubinstein; R Hichwa; A B Young
Journal:  Ann Neurol       Date:  1988-06       Impact factor: 10.422

8.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.

Authors:  Yeun Su Choo; Gail V W Johnson; Marcy MacDonald; Peter J Detloff; Mathieu Lesort
Journal:  Hum Mol Genet       Date:  2004-05-26       Impact factor: 6.150

9.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

10.  Positron emission tomography in the early diagnosis of Huntington's disease.

Authors:  M R Hayden; W R Martin; A J Stoessl; C Clark; S Hollenberg; M J Adam; W Ammann; R Harrop; J Rogers; T Ruth
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

View more
  159 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

Review 2.  Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.

Authors:  P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2014-03-28       Impact factor: 7.851

Review 3.  Huntington's Disease and Mitochondria.

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi
Journal:  Neurotox Res       Date:  2017-06-21       Impact factor: 3.911

4.  Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease.

Authors:  P Hemachandra Reddy; Maria Manczak; XiangLing Yin
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  Mitochondrial protein quality control in health and disease.

Authors:  Michael J Baker; Catherine S Palmer; Diana Stojanovski
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 6.  Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo?

Authors:  Nadia Cummins; Jürgen Götz
Journal:  Cell Mol Life Sci       Date:  2017-10-30       Impact factor: 9.261

7.  Modelling the molecular mechanism of protein-protein interactions and their inhibition: CypD-p53 case study.

Authors:  S M Fayaz; G K Rajanikant
Journal:  Mol Divers       Date:  2015-07-14       Impact factor: 2.943

Review 8.  Mitochondria: the next (neurode)generation.

Authors:  Eric A Schon; Serge Przedborski
Journal:  Neuron       Date:  2011-06-23       Impact factor: 17.173

9.  Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Authors:  Jiu-Qiang Wang; Qian Chen; Xianhua Wang; Qiao-Chu Wang; Yun Wang; He-Ping Cheng; Caixia Guo; Qinmiao Sun; Quan Chen; Tie-Shan Tang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 10.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.